TEST CHANGE

B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry

3000724, B-ALL MRD

Specimen Requirements:	
Patient Preparation:	
Collect:	Bone marrow aspirate or whole~~. Whole~~ blood: g~~G~~reen (sodium heparin) or lavender (EDTA).
Specimen Preparation:	Transport 2 mL heparinized bone marrow aspirate (Min: 1.0 mL) OR 3 mL whole blood (Min: 1.0 mL)
Transport Temperature:	Room temperature. Also acceptable: Refrigerated. Specimen should be received within 24 hours of collection for optimal cell viability.
Unacceptable Conditions:	Clotted or hemolyzed specimens.
Remarks:	Provide specimen source, CBC, Wright-stained smear (if available), clinical history, differential diagnosis. Follow up: If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen.
Stability:	Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology:	Flow Cytometry
Performed:	Sun-Sat
Reported:	1-3 days
Note:	This assay is a minimal residual disease assessment of B-ALL by flow cytometry. Available markers*: CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16, CD66b, CD24, CD22 *Not all markers will be reported in all cases. The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers or 9-15 markers interpreted. Charges apply per marker.
CPT Codes:	88184; 88185 each additional marker; 88187 or 88188.
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Interpretive Data:
Refer to report.
Reference Interval:
By Report